Asensus Surgical Inc (ASXC)

$0.271

-0.01

(-2.55%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Asensus Surgical Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 976.0K → 5.43M (in $), with an average increase of 30.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -22.21M → -17.23M (in $), with an average increase of 8.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.5% return, outperforming this stock by 94.4%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.6% return, outperforming this stock by 152.2%

Performance

  • $0.27
    $0.28
    $0.27
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.57%

    Upside

    3.57%

    downward going graph
  • $0.20
    $0.86
    $0.27
    downward going graph

    24.44%

    Downside

    52 Weeks Volatility :76.28%

    Upside

    68.6%

    downward going graph

Returns

PeriodAsensus Surgical IncSector (Health Care)Index (Russel 2000)
3 Months
-11.23%
-1.1%
0.0%
6 Months
5.04%
6.7%
0.0%
1 Year
-64.81%
3.2%
-0.7%
3 Years
-85.59%
15.2%
-21.6%

Highlights

Market Capitalization
74.8M
Book Value
$0.13
Earnings Per Share (EPS)
-0.31
Wall Street Target Price
0.35
Profit Margin
0.0%
Operating Margin TTM
-282.34%
Return On Assets TTM
-55.76%
Return On Equity TTM
-117.89%
Revenue TTM
8.6M
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
120.39999999999999%
Gross Profit TTM
-3.8M
EBITDA
-74.4M
Diluted Eps TTM
-0.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.18
EPS Estimate Next Year
-0.14
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Asensus Surgical Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 29.15%

Current $0.27
Target $0.35

Company Financials

FY18Y/Y Change
Revenue
24.1M
↑ 238.94%
Net Income
-61.8M
↓ 57.34%
Net Profit Margin
-256.31%
↑ 1779.92%
FY19Y/Y Change
Revenue
8.5M
↓ 64.6%
Net Income
-154.2M
↑ 149.61%
Net Profit Margin
-1.8K%
↓ 1551.23%
FY20Y/Y Change
Revenue
3.2M
↓ 62.78%
Net Income
-59.3M
↓ 61.54%
Net Profit Margin
-1.9K%
↓ 60.55%
FY21Y/Y Change
Revenue
8.2M
↑ 159.28%
Net Income
-62.5M
↑ 5.31%
Net Profit Margin
-758.77%
↑ 1109.32%
FY22Y/Y Change
Revenue
7.1M
↓ 13.91%
Net Income
-75.6M
↑ 20.97%
Net Profit Margin
-1.1K%
↓ 307.42%
FY23Y/Y Change
Revenue
8.6M
↑ 21.02%
Net Income
-78.4M
↑ 3.8%
Net Profit Margin
-914.46%
↑ 151.73%
Q3 FY22Q/Q Change
Revenue
2.6M
↑ 157.85%
Net Income
-18.9M
↓ 3.54%
Net Profit Margin
-738.35%
↑ 1235.39%
Q4 FY22Q/Q Change
Revenue
2.5M
↓ 3.86%
Net Income
-17.9M
↓ 5.46%
Net Profit Margin
-726.06%
↑ 12.29%
Q1 FY23Q/Q Change
Revenue
976.0K
↓ 60.39%
Net Income
-22.2M
↑ 24.19%
Net Profit Margin
-2.3K%
↓ 1550.37%
Q2 FY23Q/Q Change
Revenue
1.1M
↑ 10.76%
Net Income
-20.7M
↓ 7.0%
Net Profit Margin
-1.9K%
↑ 365.05%
Q3 FY23Q/Q Change
Revenue
1.1M
↑ 0.74%
Net Income
-18.3M
↓ 11.34%
Net Profit Margin
-1.7K%
↑ 229.29%
Q4 FY23Q/Q Change
Revenue
5.4M
↑ 398.71%
Net Income
-17.2M
↓ 5.91%
Net Profit Margin
-317.34%
↑ 1364.75%
FY18Y/Y Change
Total Assets
239.3M
↓ 4.37%
Total Liabilities
70.8M
↓ 0.86%
FY19Y/Y Change
Total Assets
74.8M
↓ 68.75%
Total Liabilities
19.2M
↓ 72.81%
FY20Y/Y Change
Total Assets
78.3M
↑ 4.65%
Total Liabilities
16.7M
↓ 13.28%
FY21Y/Y Change
Total Assets
186.5M
↑ 138.28%
Total Liabilities
17.2M
↑ 3.22%
FY22Y/Y Change
Total Assets
116.1M
↓ 37.76%
Total Liabilities
16.4M
↓ 4.75%
FY23Y/Y Change
Total Assets
60.5M
↓ 47.84%
Total Liabilities
27.1M
↑ 65.29%
Q3 FY22Q/Q Change
Total Assets
128.7M
↓ 12.69%
Total Liabilities
15.7M
↓ 1.47%
Q4 FY22Q/Q Change
Total Assets
116.1M
↓ 9.79%
Total Liabilities
16.4M
↑ 4.66%
Q1 FY23Q/Q Change
Total Assets
96.5M
↓ 16.83%
Total Liabilities
16.8M
↑ 2.43%
Q2 FY23Q/Q Change
Total Assets
78.4M
↓ 18.81%
Total Liabilities
16.9M
↑ 0.37%
Q3 FY23Q/Q Change
Total Assets
70.7M
↓ 9.75%
Total Liabilities
23.5M
↑ 39.16%
Q4 FY23Q/Q Change
Total Assets
60.5M
↓ 14.41%
Total Liabilities
27.1M
↑ 15.53%
FY18Y/Y Change
Operating Cash Flow
-48.5M
↑ 21.86%
Investing Cash Flow
-53.5M
↓ 1070.79%
Financing Cash Flow
26.5M
↓ 74.66%
FY19Y/Y Change
Operating Cash Flow
-73.5M
↑ 51.54%
Investing Cash Flow
67.6M
↓ 226.48%
Financing Cash Flow
-5.6M
↓ 121.2%
FY20Y/Y Change
Operating Cash Flow
-46.7M
↓ 36.48%
Investing Cash Flow
-3.0K
↓ 100.0%
Financing Cash Flow
53.4M
↓ 1051.51%
FY21Y/Y Change
Operating Cash Flow
-40.7M
↓ 12.89%
Investing Cash Flow
-119.7M
↑ 3988833.33%
Financing Cash Flow
161.7M
↑ 202.99%
FY22Y/Y Change
Operating Cash Flow
-58.9M
↑ 44.95%
Investing Cash Flow
47.5M
↓ 139.72%
Financing Cash Flow
-332.0K
↓ 100.21%
Q3 FY22Q/Q Change
Operating Cash Flow
-14.7M
↑ 2.57%
Investing Cash Flow
18.0M
↑ 13991.41%
Financing Cash Flow
-1000.0
↓ 120.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-14.1M
↓ 4.1%
Investing Cash Flow
6.3M
↓ 64.92%
Financing Cash Flow
194.0K
↓ 19500.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-17.2M
↑ 22.74%
Investing Cash Flow
29.7M
↑ 370.0%
Financing Cash Flow
-483.0K
↓ 348.97%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.0M
↑ 4.1%
Investing Cash Flow
6.6M
↓ 77.93%
Financing Cash Flow
194.0K
↓ 140.17%

Technicals Summary

Sell

Neutral

Buy

Asensus Surgical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Asensus Surgical Inc
Asensus Surgical Inc
-3.21%
5.04%
-64.81%
-85.59%
-93.36%
Stryker Corporation
Stryker Corporation
-2.89%
29.52%
16.83%
33.17%
76.84%
Boston Scientific Corp.
Boston Scientific Corp.
2.78%
35.87%
31.56%
66.59%
80.03%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.2%
26.67%
7.41%
2.59%
43.13%
Abbott Laboratories
Abbott Laboratories
-5.52%
18.37%
4.39%
-11.97%
40.79%
Medtronic Plc
Medtronic Plc
-4.12%
11.68%
-2.42%
-36.33%
-7.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Asensus Surgical Inc
Asensus Surgical Inc
NA
NA
NA
-0.18
-1.18
-0.56
NA
0.13
Stryker Corporation
Stryker Corporation
42.0
42.0
2.96
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
64.16
64.16
1.81
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.74
39.74
5.26
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
34.1
34.1
6.1
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
26.14
26.14
1.56
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Asensus Surgical Inc
Asensus Surgical Inc
Buy
$74.8M
-93.36%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$132.1B
76.84%
42.0
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.9B
80.03%
64.16
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$55.0B
43.13%
39.74
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$192.9B
40.79%
34.1
14.27%
Medtronic Plc
Medtronic Plc
Buy
$109.3B
-7.76%
26.14
13.0%

Corporate Announcements

  • Asensus Surgical Inc Earnings

    Asensus Surgical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

asensus aps is a computer software company based out of 22a vallensbækvej, brondby, capital region of denmark, denmark.

Organization
Asensus Surgical Inc
Employees
207
CEO
Mr. Anthony Fernando
Industry
Healthcare

FAQs